Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06560086
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-15
Brief Title:
Ketoconazole Contributes to Cryptorchidism Outcome Via Modulating Macrophage Trem2
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Ketoconazole Contributes to Cryptorchidism Outcome Via Modulating Testicular Macrophage Trem2
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Reduced hormone insulin-like 3 exclusively secreted by Leydig cells has been identified as the recognized mechanism for cryptorchidism Testicular macrophages residing in the testicular interstitium were thought to play a vital role in maintaining hormone secretion of Leydig cells However the contribution of macrophages to cryptorchidism remained poorly understood Here after 14 days of ketoconazole treatment levels of both Trem2 and insulin-like 3 significantly decrease in human embryonic testes compared to the untreated control group Conversely 14 days of luteinizing hormone stimulation lead to elevated levels of Trem2 and insulin-like 3 in the testes compared to the untreated control group Additionally researchers find a positive correlation between Trem2 and insulin-like 3 expression in a human ex vivo tissue culture model In summary the study will propose Trem2 as a novel target for maintaining normal testicular descent by regulating the testicular immune microenvironment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None